Hong Kong-based genomic and diagnostic testing business Prenetics slumped on its NASDAQ debut, unable to withstand struggling public markets public markets and weak investor appetite for businesses that merge with US-listed special purpose acquisition...
Multiples Private Equity has led a consortium in the acquisition of a 9.3% stake in India’s BDR Pharmaceuticals for INR 6.8bn (USD 88.5m).
Japan Industrial Solutions (JIS) has agreed to invest up to JPY 20bn (USD 155m) in Japan-based generic drug manufacturer Nichi-Iko Pharmaceutical with a view to saving the troubled company.
Eight Roads Ventures has launched its first dedicated healthcare and life-sciences fund for India with a corpus of USD 250m provided entirely by its parent, Fidelity.
ICG has acquired Canopy Healthcare Group, a New Zealand-based healthcare platform that offers diagnostic imaging, medical oncology, and drug compounding services.
PAG has supported the acquisition of Optimus Drugs for an undisclosed sum alongside CX Partners and Samara Capital as part of a joint Indian pharmaceuticals platform play.
MDI Ventures, the corporate VC arm of state-controlled Telkom Indonesia, has launched a USD 20m fund with domestic vaccine manufacturer Bio Farma that will pursue early and growth-stage healthcare investments.
Reistone, a novel drug developer incubated by Jiangsu Hengrui Pharmaceuticals, has raised a Series A of nearly USD 100m led by Huagai Capital.
TPG Growth and Temasek Holdings have invested a combined INR 10.5bn (USD 136m) in Indian eyecare chain Dr. Agarwal’s Eye Hospital, setting up an exit for ADV Partners.
LeapFrog Investments has led a USD 61m round for India’s Redcliffe Lifetech, a diagnostics platform focused on non-communicable diseases, including heart disease, cancer, and diabetes.
IDG Capital has joined a Series A round of several hundred million renminbi for China’s Sustao, which is developing a platform for fully automating surgical robots.
India’s Toothsi, a direct-to-consumer start-up that makes own-branded transparent dental aligners and braces, has raised a USD 40m Series C round featuring Eight Roads Ventures.
Having started a Southeast Asia specialist, MassMutual Ventures has broadened its regional coverage to include everything outside of China. Europe is also part of the equation for Fund III
RVAC Medicines, a Singapore-based company involved in developing messenger RNA (mRNA) vaccines for COVID-19, has closed a Series B round that takes its overall funding to USD 140m.
South and Southeast Asia healthcare specialist Quadria Capital is broadening its scope to include areas such as healthcare technology and digital health insurance for Fund III, which is expected to be up to USD 1bn in size.
MassMutual Ventures (MMV), a global venture capital firm that counts US-based Massachusetts Mutual Life Insurance as its sole LP, has launched a USD 300m fund that will invest in Asia Pacific and Europe.
Biofourmis, a Singapore founded and now US-based operator of a health analytics platform, has achieved unicorn status with the closing of a USD 300m Series D round led by General Atlantic.
SoftBank Vision Fund 2 has led a JPY 8bn (USD 70m) Series C funding round for AI Medical Service, a Tokyo-based medical technology company that has developed an artificial intelligence-enabled (AI) endoscopy diagnostic solution.
Elixir, a China-based clinical research organisation (CRO), has raised a USD 52m Series A round from Lyfe Capital, Chow Tai Fook Investment, and Sinovation Ventures.
Binhui Biopharm, a Chinese biotech firm specialising in oncolytic virus immune-oncology, has raised CNY 300m (USD 47m) in an extended Series B round led by Yangtze River Pharmaceutical Group.
A KKR-led consortium has proposed to acquire Ramsay Health Care, an Australia-listed hospital operator with a footprint that encompasses Australia, Europe, and other parts of Asia, at a valuation of approximately AUD 20.1bn (USD 14.9bn).
Creaegis, an India-based private equity firm established by Prakash Parthasarathy, formerly founding CIO and managing partner of PremjiInvest, is looking to raise USD 500m for its debut fund.
Baylx, a Beijing-based drug developer that utilises stem cell technology, has raised CNY 300m （USD 47m）across two rounds - a Series B and a Series B extension.
Lighthouse Funds has led a USD 65m funding round for Medikabazaar, an India-based B2B medical supplies marketplace, at a valuation of USD 700m.